SLDB Solid Biosciences Inc.
$6.19▲ +6.54%
Healthcare
Other
Volume 1.55M
Avg Volume (10D) 1.49M
Key Metrics & Fundamentals
Market Cap
$663.72M
P/E Ratio
–
Div Yield
0.00%
52W Range
3.79 - 11.45
% vs 50 MA
-22.53%
% vs 200 MA
-19.04%
RSI-14
41.4
MACD Histogram
+0.0800
Beta (1Y vs SPY)
2.10
Free Cash Flow
-$52.74M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$53.56M
COGS
–
Operating Exp
$57.38M
Operating Income
-$57.38M
EBIT
-$57.38M
Pretax Income
-$54.80M
Net Income
-$54.80M
EPS (Diluted)
-0.38
Price & Volume History
Loading chart…
Recent News
Solid Biosciences Receives EU Orphan Designation for SGT-212 in Friedreich's Ataxia
MT Newswires · Oct 26, 2026 9:29 AM ET
Solid Biosciences Announces European Commission Orphan Designation for SGT-212 and Continued Progress in the FALCON Trial in Friedreich’s Ataxia
GlobeNewswire · Oct 26, 2026 8:00 AM ET
Solid Biosciences to Present Research Across Gene Therapy Development, Delivery and Manufacturing at ESGCT 2026
GlobeNewswire · Oct 20, 2026 8:00 AM ET
UBS Initiates Solid Biosciences at Buy With $20 Price Target
MT Newswires · Oct 15, 2026 8:11 AM ET
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · Oct 1, 2026 4:05 PM ET
Solid Biosciences' Duchenne Muscular Dystrophy Approach, FDA Shift Support Upside, RBC Says
MT Newswires · Sep 16, 2026 11:16 AM ET
RBC Initiates Solid Biosciences at Outperform, Speculative Risk With $18 Price Target
MT Newswires · Sep 16, 2026 6:24 AM ET
Solid Biosciences to Participate at Upcoming Investor Conferences
GlobeNewswire · Sep 2, 2026 8:00 AM ET
Wedbush Adjusts PT on Solid Biosciences to $15 From $16, Maintains Outperform Rating
MT Newswires · Aug 7, 2026 11:02 AM ET
Solid Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Updates
GlobeNewswire · Aug 6, 2026 4:08 PM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See SLDB's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.